Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
By allowing this, you consent to storing study selections locally on your device. Privacy Policy
How to NavigateConnectDistinguished InvestigatorsConferencesEducationRLT ComponentsSponsorsTrial Stats
A Phase 1 Neoadjuvant Trial of Selective Internal Yttrium-90 Radioembolization (SIRT) With Tremelimumab and Durvalumab (MEDI4736) for Resectable Hepatocellular Carcinoma
Description:
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery.
Sponsor:
Dana-Farber Cancer Institute
Government Study Link:
NCT05701488 - Click here to see study onClinicalTrials.gov
